Abstract:Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clinical trials. Recently, dual targeting strategy comprising the HDACs component has emerged as an alternative approach for combination therapies. In this perspective, we intend to gather all HDACs-containing dual inhibitors related to cancer therapy published in literature since 2015, classify them into five categories based on targets' biological functions, and discuss the rationale why dual acting agents should work better than combinatorial therapies using two separate drugs. The article discusses the pharmacological aspects of these dual inhibitors, including in vitro biological activities, pharmacokinetic studies, in vivo efficacy studies, as well as available clinical trials. The review of the current status and advances should provide better analysis for future opportunities and challenges of this field.

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

Targeting histone deacetylases for cancer therapy: Trends and challenges

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Selective Histone Deacetylase Inhibitors with Anticancer Activity.

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

HDAC-targeting epigenetic modulators for cancer immunotherapy

Medicinal Chemistry Insights into Novel HDAC Inhibitors: an Updated Patent Review (2012-2016).

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Next-generation of Selective Histone Deacetylase Inhibitors

Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)

An Update On The Emerging Approaches For Histone Deacetylase (Hdac) Inhibitor Drug Discovery And Future Perspectives

New Development of HDAC Inhibitors As Anti-Cancer Agents

Hydroxamic Acid Hybrids: Histone Deacetylase Inhibitors with Anticancer Therapeutic Potency

An Overview of HDAC Inhibitors and Their Synthetic Routes.